Annual report
6523.TEDINET S100W5A5
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥361.6bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥353.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥356.4bn | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥306.1bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥22.6bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.6bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥18.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥179m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥22.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥10.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥12.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥3.2bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥16.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥10.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥12.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥532.5bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥564.3bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥561.6bn | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥591.3bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥569.3bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥391.3bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥425.2bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥141.2bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥139.2bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥138.8bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥141.6bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥139.5bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥138.0bn | at 2023-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥135.4bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥107.0bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥39.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥60.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥41.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥41.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥21.4bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥47.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥8.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥21.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥17.5bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥16.3bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥39.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥39.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥40.8bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥20.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥83.13 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-25.84 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥149.07 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥82.58 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-25.84 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥143.93 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,122.36 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,106.98 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,101.33 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,092.33 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥921.04 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 26.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.6% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 7.5% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -9.3% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -2.4% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -7.0% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 19.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 9,041 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 9,245 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 9,403 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 9,374 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 9,753 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥16.2bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥39.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥32.9bn | 2022-04-01 → 2023-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥39.2bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥8.8bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥8.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥30.1bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.8bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥23.3bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.7bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.0bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥4.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥7.9bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥11.1bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥7.9bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥16.4bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥19.3bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.9bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥132m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥431.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥467.1bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥457.3bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥467.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥432.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥332.4bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥372.3bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥98.7bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥94.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥96.7bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥96.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥50.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥10.2bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥11.5bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥62.39 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥130.25 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.96 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥166.62 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.17 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥62.13 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥129.59 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥153.15 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥161.08 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥42 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥38 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥778.8 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥751.98 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥759.31 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥763.79 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥428.12 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 22.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.3% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 11.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 20.4% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 27.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 126,410,072 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 126,244,271 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,522,074 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 124,144,242 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 114,831,084 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 176 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 141 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 151 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 175 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 181 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 288 pure |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥7.8bn |
| Diabetes Managementreportable segment | employees | at 2025-03-31 | 1425 pure |
| Diabetes Managementreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥98.7bn |
| Diabetes Managementreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥98.7bn |
| Diabetes Managementreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥13.9bn |
| Diagnostics And Life Sciencesreportable segment | employees | at 2025-03-31 | 3555 pure |
| Diagnostics And Life Sciencesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥130.9bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥130.9bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Healthcare Solutionsreportable segment | employees | at 2025-03-31 | 3773 pure |
| Healthcare Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥128.3bn |
| Healthcare Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥128.3bn |
| Healthcare Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥9.3bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥357.9bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥357.9bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥30.4bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥10.6bn |
| Diabetes Managementreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥101.6bn |
| Diabetes Managementreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥101.6bn |
| Diabetes Managementreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥16.0bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥129.7bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥129.7bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥5.6bn |
| Healthcare Solutionsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥120.3bn |
| Healthcare Solutionsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥120.3bn |
| Healthcare Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥9.4bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥351.5bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥351.5bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥12.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 176 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,961
| Item | Context | Value | Unit |
|---|---|---|---|
| Payout ratio (5-year summary) | Prior4YearDuration_NonConsolidatedMember | － | |
| Payout ratio (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 0.228 | |
| Payout ratio (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 0.465 | |
| Payout ratio (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 0.415 | |
| Payout ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 0.673 | |
| Number of employees | Prior4YearInstant_NonConsolidatedMember | 181 | |
| Number of employees | Prior3YearInstant_NonConsolidatedMember | 175 | |
| Number of employees | Prior2YearInstant_NonConsolidatedMember | 151 | |
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 141 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 176 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 14 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 15 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 16 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 15 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 20 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | － | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | － | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.853 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.774 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.679 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | － | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | － | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.058 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.496 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.472 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E36976-000DiabetesManagementReportableSegmentMember | 1425 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E36976-000DiabetesManagementReportableSegmentMember | 9 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E36976-000HealthcareSolutionsReportableSegmentMember | 3773 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E36976-000HealthcareSolutionsReportableSegmentMember | 1702 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 3555 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 279 | |
| Number of employees | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 288 | |
| Average number of temporary workers | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 41 | |
| Number of employees | CurrentYearInstant | 9041 | |
| Average number of temporary workers | CurrentYearInstant | 2031 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 176 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 20 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 48.8 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 18.8 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 9177383 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 176 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 20 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 176 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 20 | |
| Ratio of female employees in managerial positions metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.268 | |
| All employees calculated based on provisions of article714 item1 of ordinance for enforcement of act on childcare leave caregiver leave and other measures for the welfare of workers caring for children or other family members ratio of male employees taking childcare leave metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | － | |
| All employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.827 | |
| Regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.821 | |
| Non regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | － | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.103 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |